These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15829505)

  • 21. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
    Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
    J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. YAC128 mouse model of Huntington disease is protected against subtle chronic manganese (Mn)-induced behavioral and neuropathological changes.
    Wilcox JM; Pfalzer AC; Tienda AA; Debbiche IF; Cox EC; Totten MS; Erikson KM; Harrison FE; Bowman AB
    Neurotoxicology; 2021 Dec; 87():94-105. PubMed ID: 34543681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease.
    Sutton LM; Sanders SS; Butland SL; Singaraja RR; Franciosi S; Southwell AL; Doty CN; Schmidt ME; Mui KK; Kovalik V; Young FB; Zhang W; Hayden MR
    Hum Mol Genet; 2013 Feb; 22(3):452-65. PubMed ID: 23077216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testicular degeneration in Huntington disease.
    Van Raamsdonk JM; Murphy Z; Selva DM; Hamidizadeh R; Pearson J; Petersén A; Björkqvist M; Muir C; Mackenzie IR; Hammond GL; Vogl AW; Hayden MR; Leavitt BR
    Neurobiol Dis; 2007 Jun; 26(3):512-20. PubMed ID: 17433700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
    Boudreau RL; McBride JL; Martins I; Shen S; Xing Y; Carter BJ; Davidson BL
    Mol Ther; 2009 Jun; 17(6):1053-63. PubMed ID: 19240687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice.
    Pouladi MA; Stanek LM; Xie Y; Franciosi S; Southwell AL; Deng Y; Butland S; Zhang W; Cheng SH; Shihabuddin LS; Hayden MR
    Hum Mol Genet; 2012 May; 21(10):2219-32. PubMed ID: 22328089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.
    Moreno CL; Ehrlich ME; Mobbs CV
    Neurobiol Dis; 2016 Jan; 85():25-34. PubMed ID: 26485309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.
    Graham RK; Pouladi MA; Joshi P; Lu G; Deng Y; Wu NP; Figueroa BE; Metzler M; André VM; Slow EJ; Raymond L; Friedlander R; Levine MS; Leavitt BR; Hayden MR
    J Neurosci; 2009 Feb; 29(7):2193-204. PubMed ID: 19228972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.
    Gil-Mohapel JM
    CNS Neurosci Ther; 2012 Jan; 18(1):77-86. PubMed ID: 21501423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
    Caron NS; Byrne LM; Lemarié FL; Bone JN; Aly AE; Ko S; Anderson C; Casal LL; Hill AM; Hawellek DJ; McColgan P; Wild EJ; Leavitt BR; Hayden MR
    Transl Neurodegener; 2024 Oct; 13(1):50. PubMed ID: 39380076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
    Stanek LM; Bu J; Shihabuddin LS
    Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neural stem cells derived from the developing forebrain of YAC128 mice exhibit pathological features of Huntington's disease.
    Li E; Park HR; Hong CP; Kim Y; Choi J; Lee S; Park HJ; Lee B; Kim TA; Kim SJ; Kim HS; Song J
    Cell Prolif; 2020 Oct; 53(10):e12893. PubMed ID: 32865873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.
    Silva AC; Ferreira IL; Hayden MR; Ferreiro E; Rego AC
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):34-44. PubMed ID: 28939435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease.
    Carroll JB; Lerch JP; Franciosi S; Spreeuw A; Bissada N; Henkelman RM; Hayden MR
    Neurobiol Dis; 2011 Jul; 43(1):257-65. PubMed ID: 21458571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant palmitoylation in Huntington disease.
    Sanders SS; Hayden MR
    Biochem Soc Trans; 2015 Apr; 43(2):205-10. PubMed ID: 25849918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.
    Slow EJ; Graham RK; Osmand AP; Devon RS; Lu G; Deng Y; Pearson J; Vaid K; Bissada N; Wetzel R; Leavitt BR; Hayden MR
    Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11402-7. PubMed ID: 16076956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense oligonucleotide-mediated disruption of HTT caspase-6 cleavage site ameliorates the phenotype of YAC128 Huntington disease mice.
    Kuijper EC; Overzier M; Suidgeest E; Dzyubachyk O; Maguin C; Pérot JB; Flament J; Ariyurek Y; Mei H; Buijsen RAM; van der Weerd L; van Roon-Mom W
    Neurobiol Dis; 2024 Jan; 190():106368. PubMed ID: 38040383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.